Literature DB >> 1970492

Effect of the nootropic drug oxiracetam on field potentials of rat hippocampal slices.

A M Pugliese1, R Corradetti, L Ballerini, G Pepeu.   

Abstract

1. The effect of the nootropic drug oxiracetam on hippocampal neurotransmission was investigated in the CA1 region of the rat hippocampal slice in vitro by use of extracellular recordings. 2. Superfusion of oxiracetam (0.1-100 microM) produced a concentration-dependent, wash-resistant (greater than 90 min), increase in initial slope and amplitude of the dendritic field excitatory postsynaptic potential (e.p.s.p.). This increase was maximal at a concentration of 1 microM (70%). 3. Input-output curves relating the initial slope to the amplitude of the afferent volley were significantly (P less than 0.05) steeper and showed a greater maximal response in the presence of 1 microM oxiracetam than in control conditions. 4. Two trains of high frequency stimulation (100 Hz, 0.4 s, 5 min apart) delivered in the stratum radiatum 30 min after washout of oxiracetam (1 microM) still elicited a long-term potentiation (LTP) of the field e.p.s.p. However, the absolute magnitude of the LTP produced did not differ from that obtained in untreated slices. 5. After induction and establishment of LTP, oxiracetam (1 microM) had a smaller (27%) and reversible effect on the evoked field e.p.s.p. 6. D-2-Amino-5-phosphonopentanoic acid (AP-5), at the same concentration (50 microM) which in our conditions prevented the induction of LTP, blocked the action of 1 microM oxiracetam and strongly depressed the effect of higher concentrations of the nootropic drug. 7. It is concluded that oxiracetam provokes an enduring increase of neurotransmission in the CA1 rat hippocampal region. This action appears to share some features with LTP as indicated by its persistence, sensitivity to AP-5 and lack of additivity with electrically-induced LTP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970492      PMCID: PMC1917508          DOI: 10.1111/j.1476-5381.1990.tb14676.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Long-term potentiation in the hippocampus of the anaesthetized rat is not associated with a sustained enhanced release of endogenous excitatory amino acids.

Authors:  L Aniksztejn; M P Roisin; R Amsellem; Y Ben-Ari
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

Review 2.  Cognition activators.

Authors:  W H Moos; R E Davis; R D Schwarz; E R Gamzu
Journal:  Med Res Rev       Date:  1988 Jul-Sep       Impact factor: 12.944

Review 3.  Long-term synaptic potentiation.

Authors:  T H Brown; P F Chapman; E W Kairiss; C L Keenan
Journal:  Science       Date:  1988-11-04       Impact factor: 47.728

Review 4.  The current excitement in long-term potentiation.

Authors:  R A Nicoll; J A Kauer; R C Malenka
Journal:  Neuron       Date:  1988-04       Impact factor: 17.173

5.  Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine.

Authors:  M L Mayer; L Vyklicky; J Clements
Journal:  Nature       Date:  1989-03-30       Impact factor: 49.962

6.  2-Amino-5-phosphonovalerate (2APV), a potent and selective antagonist of amino acid-induced and synaptic excitation.

Authors:  J Davies; A A Francis; A W Jones; J C Watkins
Journal:  Neurosci Lett       Date:  1981-01-01       Impact factor: 3.046

7.  Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine.

Authors:  G Spignoli; G Pepeu
Journal:  Pharmacol Biochem Behav       Date:  1987-07       Impact factor: 3.533

8.  Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.

Authors:  R Cumin; E F Bandle; E Gamzu; W E Haefely
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  Different susceptibilities of long-term potentiations in CA3 and CA1 regions of guinea pig hippocampal slices to nootropic drugs.

Authors:  M Satoh; K Ishihara; H Katsuki
Journal:  Neurosci Lett       Date:  1988-11-11       Impact factor: 3.046

10.  Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus.

Authors:  G L Collingridge; S J Kehl; H McLennan
Journal:  J Physiol       Date:  1983-01       Impact factor: 5.182

View more
  6 in total

1.  Comparative kinetics of oxiracetam in serum and CSF of patients with dementia of Alzheimer type.

Authors:  L Parnetti; P Mecocci; A Gaiti; D Cadini; F Lombardi; M Visconti; U Senin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

2.  Oxiracetam and D-pyroglutamic acid antagonize a disruption of passive avoidance behaviour induced by the N-methyl-D-aspartate receptor antagonist 2-amino-5-phosphonovalerate.

Authors:  F Paoli; G Spignoli; G Pepeu
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Oxiracetam antagonizes the disruptive effects of scopolamine on memory in the radial maze.

Authors:  M Magnani; O Pozzi; R Biagetti; S Banfi; L Dorigotti
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  Modulating effect of the nootropic drug, piracetam on stress- and subsequent morphine-induced prolactin secretion in male rats.

Authors:  A Matton; S Engelborghs; F Bollengier; E Finné; L Vanhaeist
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

5.  MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties.

Authors:  J A Miller; M W Dudley; J H Kehne; S M Sorensen; J M Kane
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

Review 6.  Clinical pharmacokinetics of drugs for Alzheimer's disease.

Authors:  L Parnetti
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.